Novel compounds

Abstract

The present invention provides compounds of formula (I) wherein n, p, R 1 , R 2 , X 1 , X 2 , X 3 , X 4 , X 5 , R 3a , R 3b , R 4 , R 5 and R 6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.

1 - 16 . (canceled) 
     
     
         17 . A compound or a pharmaceutically acceptable salt thereof, wherein the compound has the structure: 
       
         
           
           
               
               
           
         
       
     
     
         18 . A pharmaceutically acceptable salt of the compound of  claim 17 , wherein the pharmaceutically acceptable salt comprises a hydrochloride, hydrobromide, trifluoroacetate, sulphate, phosphate, acetate, fumarate, maleate, tartrate, lactate, citrate, pyruvate, succinate, oxalate, methanesulphonate or p-toluenesulphonate salt. 
     
     
         19 . A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof as claimed in  claim 17  and a pharmaceutically acceptable adjuvant, diluent or carrier. 
     
     
         20 . A pharmaceutical composition as claimed in  claim 19 , wherein the composition is an inhalation composition. 
     
     
         21 . A process for the preparation of a pharmaceutical composition as claimed in  claim 19  which comprises mixing the compound or pharmaceutically acceptable salt thereof with a pharmaceutically acceptable adjuvant, diluent or carrier. 
     
     
         22 . A method of treating, or reducing the risk of, an obstructive airways disease or condition which comprises administering to a patient in need thereof a therapeutically effective amount of a compound or pharmaceutically acceptable salt thereof as claimed in  claim 17 . 
     
     
         23 . A method as claimed in  claim 22 , wherein the disease or condition is chronic obstructive pulmonary disease. 
     
     
         24 . A method as claimed in  claim 22 , wherein the disease or condition is asthma. 
     
     
         25 . A method of treating allergic rhinitis which comprises administering to a patient in need thereof a therapeutically effective amount of a compound or pharmaceutically acceptable salt thereof as claimed in  claim 17 . 
     
     
         26 . The method as claimed in  claim 22 , wherein the therapeutically effective amount of the compound or pharmaceutically acceptable salt thereof is administered by a dry powder inhaler. 
     
     
         27 . A combination comprising a compound according to  claim 17 , or a pharmaceutically acceptable salt thereof, and one or more agents independently selected from:
 a non-steroidal glucocorticoid receptor agonist;   a selective β2 adrenoreceptor agonist;   a phosphodiesterase inhibitor;   a protease inhibitor;   a glucocorticoid;   an anticholinergic agent;   a modulator of chemokine receptor function; and   an inhibitor of kinase function.